Heliclar (Clarithromycin)

Heliclar, containing clarithromycin, is indicated for the treatment of a variety of bacterial infections that are known to be responsive to macrolide therapy.

• Community‑acquired pneumonia caused by susceptible Streptococcus pneumoniae and atypical pathogens.
• Acute bacterial sinusitis and acute exacerbations of chronic bronchitis.
• Skin and soft‑tissue infections such as cellulitis and erysipelas.
• Part of combination therapy for Helicobacter pylori eradication.
• Certain atypical mycobacterial infections when alternative agents are unsuitable.

Side effects of Heliclar reflect the known safety profile of clarithromycin. Common adverse events are usually mild and transient.

Common

• Nausea or upset stomach.
• Diarrhea or loose stools.
• Abdominal pain or cramping.
• Altered taste sensation (metallic or bitter).
• Headache.

Serious

• Severe allergic reactions such as anaphylaxis or rash.
• QT interval prolongation leading to cardiac arrhythmias.
• Hepatotoxicity manifested by jaundice or elevated liver enzymes.
• Clostridioides difficile‑associated diarrhea or pseudomembranous colitis.

Before prescribing Heliclar, clinicians should evaluate several safety considerations.

• Known hypersensitivity to clarithromycin, other macrolides, or any component of the product.
• Pre‑existing liver disease, as clarithromycin is metabolized hepatically.
• Significant renal impairment may require dosage adjustment.
• Patients with a history of QT prolongation or taking other QT‑prolonging drugs.
• Concomitant use of drugs that are strong CYP3A4 substrates or inhibitors.
• Pregnancy and breastfeeding status is not clearly established; use only if benefit outweighs risk.

Heliclar can affect, or be affected by, a range of other medications. Some combinations should be avoided, while others require careful monitoring.

Avoid

• Other QT‑prolonging agents (e.g., cisapride, pimozide).
• Ergot alkaloids, due to risk of ergotism.
• Statins metabolized by CYP3A4 such as simvastatin and lovastatin.

Use with caution

• Anticoagulants like warfarin, which may have increased INR.
• Anticonvulsants (carbamazepine, phenytoin) that can reduce clarithromycin levels.
• Oral contraceptives, as efficacy may be decreased.
• Digoxin and colchicine, which may require dose adjustments.
• Other CYP3A4 substrates, including certain calcium channel blockers.